Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.Ask about treatment

Bladder cancer (urothelial carcinoma): US-approved treatments and how families in the Gulf can access them

Name: Bladder cancer: US-approved treatments and Gulf access | Reserve Meds
Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Bladder cancer: the short answer

The US FDA has approved four medicines covered on this page for bladder cancer, each for a specific group of patients: Padcev ejfv, Keytruda, Opdivo and Anktiva. On 17 October 2026, four of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Padcev ejfv, Keytruda, Opdivo and Anktiva.
Gulf registers (checked 17 October 2026): see each medicine below.
Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is bladder cancer?

Bladder cancer is cancer that starts in the bladder, the organ that stores urine. US labels describe bladder cancer medicines by stage, such as non-muscle invasive or muscle invasive bladder cancer, and by the term urothelial carcinoma.^{[1, 2, 3]}

Treatment depends on the stage and grade of the cancer, your overall health and your preferences. Surgery is the main treatment. Early tumors can be removed through a cystoscope (transurethral resection), and some patients need part or all of the bladder removed (cystectomy).^[1]

Chemotherapy may be given before surgery to shrink the tumor, and after surgery some patients receive chemotherapy, radiation therapy, immunotherapy or targeted therapy to lower the risk that the cancer comes back.^{[1, 2]}

Bladder cancer in the Gulf

A 2025 study in the Saudi Medical Journal reviewed trends in genitourinary tumors at an academic center over 16 years.^[4]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 4 of 4 were listed in Saudi Arabia and 3 of 4 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.^{[5, 6]}

US FDA-approved medicines for bladder cancer

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Padcev ejfv (enfortumab vedotin-ejfv)
US FDA-approved for adults with muscle-invasive bladder cancer before and after cystectomy, and locally advanced or metastatic urothelial cancer, in combination with pembrolizumab. It is an antibody-drug conjugate given by infusion.^[2]
Current US label version: 4 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Keytruda (pembrolizumab)
US FDA-approved for urothelial cancer in several settings, including with Padcev for locally advanced or metastatic disease, and BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ. It is an immunotherapy infusion.^[7]
Current US label version: 10 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Opdivo (nivolumab)
US FDA-approved for urothelial carcinoma: adjuvant treatment after surgery for high-risk disease, first-line treatment with cisplatin and gemcitabine, and later lines. It is an immunotherapy infusion.^[8]
Current US label version: 12 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Anktiva (nogapendekin alfa inbakicept-pmln)
US FDA-approved for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, given into the bladder together with BCG.^[3]
Current US label version: 24 June 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Oman, Egypt, Turkey, India

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.^{[9, 10]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for bladder cancer

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for bladder cancer?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Padcev ejfv, Keytruda, Opdivo and Anktiva. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Padcev ejfv available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Padcev ejfv?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

What is BCG-unresponsive bladder cancer?

It is non-muscle invasive bladder cancer that has not responded to BCG treatment given into the bladder. Anktiva with BCG, and Keytruda, are US-approved for some of these patients.

Sources for the condition-specific answers: ^{[3, 7]}

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.